“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies

Table 2 List of clinical studies on tau kinase inhibitors and phosphatase activators

Drug Class	Drug Name	Mechanism	Phase	Clinical Trial ID	Population	Status
Kinase Inhibitor	Tideglusib	Inhibits GSK3-β	Phase II	NCT01350362	Mild AD	Completed
			Phase II	NCT01049399	Mild PSP	Completed
			Phase I/II	NCT00948259	AD	Completed
	Lithium	Inhibits GSK3-β	Phase II	ISRCTN72046462	Mild AD	Completed
			Phase II	NCT00088387	AD	Completed
			Phase II	NCT01055392	MCI	Completed
			Phase I/II/III	NCT02601859	MCI	Completed
			Phase IV	NCT03185208	MCI	In Progress until 2023
	Valproate	Inhibits GSK3-β	Phase I	NCT01729598	Healthy adults	Completed
			Phase II	NCT00088387	AD	Completed
			Phase III	NCT00071721	AD	Completed
	Nilotinib	Inhibits tyrosine kinase	Phase II	NCT02947893	mild/moderate AD	Completed
Phosphatase Activator	Sodium Selenate	Activates PP2A	Phase II	ACTRN 12611001200976	Mild/moderate AD	Completed
Phosphatase Activator	Sodium Selenate	Activates PP2A	Phase II	ACTRN 12620000236998	Behavioral variant of FTD	In Progress until 2024

ISSN: 1750-1326